Combining buprenorphine and XR-naltrexone to prevent relapse in opioid use disorder
Efficacy of buprenorphine and XR-naltrexone combination for relapse prevention in opioid use disorder
This study is looking at a new way to help people with opioid use disorder by using a combination of daily buprenorphine and a long-lasting medication called naltrexone, to see if it can help them stay in treatment longer and avoid relapse.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | New York State Psychiatric Institute Dba Research Foundation for Mental Hygiene, INC NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-10640817 on NIH RePORTER |
What this research studies
This research investigates a new treatment approach for individuals with opioid use disorder (OUD) by combining buprenorphine with extended-release naltrexone. The goal is to improve retention in treatment and reduce relapse rates among patients who struggle with opioid dependence. Participants will receive daily buprenorphine alongside XR-naltrexone to assess if this combination can enhance treatment effectiveness. The study aims to address the challenges faced by patients who do not respond well to standard buprenorphine maintenance therapy.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with opioid use disorder who have not found success with traditional buprenorphine treatment alone.
Not a fit: Patients who are not diagnosed with opioid use disorder or those who have contraindications to buprenorphine or naltrexone may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a more effective treatment option for individuals with opioid use disorder, potentially reducing relapse rates and improving long-term recovery outcomes.
How similar studies have performed: While the combination of buprenorphine and XR-naltrexone is a novel approach, previous studies have shown promise in using combination therapies for addiction treatment, indicating potential for success.
Where this research is happening
New York, United States
- New York State Psychiatric Institute Dba Research Foundation for Mental Hygiene, INC — New York, United States (Active)
Researchers
- Principal investigator: Bisaga, Adam — New York State Psychiatric Institute Dba Research Foundation for Mental Hygiene, INC
- Study coordinator: Bisaga, Adam
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.